gyki 52466 has been researched along with Aura in 16 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to determine whether the anticonvulsant effect of 2, 3-benzodiazepines is also displayed in a model of in vitro epilepsy, such as the "epileptiform" hippocampal slice, we studied the effects of 2,3-benzodiazepine 1-(4-aminophenyl)-4-methyl-7, 8-methylenedioxe-5H 2,3-benzodiazepine hydrochloride (GYKI 52466) and some new 2,3-benzodiazepine derivatives on CA1 basal neuronal excitability and on CA1 epileptiform burst activity produced by 4-aminopyridine in rat hippocampal slices." | 3.70 | Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity. ( Gatta, F; Marinelli, S; Sagratella, S, 2000) |
| "Two potent glutamate antagonists, NBQX and GYKI 52466, that act selectively on non-NMDA receptors, have been tested for anticonvulsant activity in 3 models of reflex epilepsy (sound-induced seizures in DBA/2 mice and in genetically epilepsy-prone rats and photically-induced myoclonus in Papio papio) and in amygdala kindled rats." | 3.68 | The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates. ( Chapman, AG; Craggs, MD; Dürmüller, N; Meldrum, BS; Smith, SE, 1992) |
| " injections at 1-h intervals, the first dosage was given shortly after the intrastriatal injection of (S)-alpha-amino-3-hydroxy-5,7-methylisoxazole-4-propionic acid (AMPA) (2." | 1.31 | Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. ( Banczerowski-Pelyhe, I; Gulyás-Kovács, A; Takács, J; Tarnawa, I; Világi, I, 2002) |
| "There was a commensurate reduction in seizure-related neuronal loss in the limbic regions of the brain." | 1.31 | In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466. ( Lees, GJ; Leong, W, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gitto, R | 3 |
| Orlando, V | 1 |
| Quartarone, S | 1 |
| De Sarro, G | 3 |
| De Sarro, A | 3 |
| Russo, E | 1 |
| Ferreri, G | 1 |
| Chimirri, A | 3 |
| Kim, JE | 2 |
| Park, H | 2 |
| Lee, JE | 1 |
| Kim, TH | 1 |
| Kang, TC | 2 |
| Lee, DS | 1 |
| Gulyás-Kovács, A | 2 |
| Dóczi, J | 1 |
| Tarnawa, I | 3 |
| Détári, L | 1 |
| Banczerowski-Pelyhe, I | 2 |
| Világi, I | 4 |
| Takács, J | 1 |
| Kubová, H | 1 |
| Mikulecká, A | 1 |
| Mares, P | 1 |
| Rizzo, M | 2 |
| Sinopoli, VA | 1 |
| Zappala, M | 2 |
| Spagnolo, C | 1 |
| Scotto, G | 1 |
| Barna, B | 2 |
| Szente, M | 2 |
| Szász, A | 2 |
| Marinelli, S | 1 |
| Gatta, F | 1 |
| Sagratella, S | 1 |
| Szabados, T | 1 |
| Gigler, G | 1 |
| Gyertyán, I | 1 |
| Gacsályi, I | 1 |
| Lévay, G | 1 |
| Kapus, G | 1 |
| Székely, JI | 1 |
| Durand, J | 1 |
| Ruiz, A | 1 |
| Lees, GJ | 1 |
| Leong, W | 1 |
| Meldrum, BS | 2 |
| Craggs, MD | 1 |
| Dürmüller, N | 2 |
| Smith, SE | 2 |
| Chapman, AG | 1 |
16 other studies available for gyki 52466 and Aura
| Article | Year |
|---|---|
Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Benzodiazepines; | 2003 |
PTEN Is Required for The Anti-Epileptic Effects of AMPA Receptor Antagonists in Chronic Epileptic Rats.
Topics: Animals; Benzodiazepines; Chronic Disease; Down-Regulation; Epilepsy; Hippocampus; Male; Models, Bio | 2020 |
Src/CK2/PTEN-Mediated GluN2B and CREB Dephosphorylations Regulate the Responsiveness to AMPA Receptor Antagonists in Chronic Epilepsy Rats.
Topics: Animals; Benzodiazepines; Casein Kinase II; Cyclic AMP Response Element-Binding Protein; Epilepsy; E | 2020 |
Comparison of spontaneous and evoked epileptiform activity in three in vitro epilepsy models.
Topics: 2-Amino-5-phosphonovalerate; 4-Aminopyridine; Animals; Anti-Anxiety Agents; Benzodiazepines; Bicucul | 2002 |
Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Anti-Anxiety Ag | 2002 |
Non-NMDA receptor antagonist GYKI 52466 suppresses cortical afterdischarges in immature rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cerebral Cortex; Electric Stimulation; Electrodes, Im | 1997 |
Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Epilepsy; Motor Activity; Motor Skil | 1998 |
Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Epilepsy; Male; Motor Activity; Post | 1999 |
The anticonvulsive effect of non-NMDA antagonist GYKI 52466 on 3-aminopyridine-induced primary and secondary cortical ictal activity in rat.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cerebral Cortex; Epi | 1999 |
Anticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in rat.
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cerebral Cortex; El | 2000 |
Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity.
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Axons; Benzodiazepines; Calcium Chan | 2000 |
Duration of action of GYKI 52466 and its analogues in antiepileptic, anti-ischaemic and muscle relaxant tests.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antag | 1999 |
AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Dose-Response Relationship, Drug; Epilepsy; Excitator | 2000 |
In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 2001 |
The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates.
Topics: Acoustic Stimulation; Amygdala; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cere | 1992 |
The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Benzodiazepin | 1991 |